N-甲酰甲硫氨酸肽驱动特发性炎性肌病中性粒细胞活化
本研究检测皮肌炎(DM)和包涵体肌炎(IBM)患者血浆fMET水平及其与中性粒细胞活化的关系。DM和IBM患者血浆fMET显著高于健康对照,fMET与抗体阴性IBM的MMT8呈负相关。FPR1抑制可显著降低DM和IBM血浆诱导的中性粒细胞活化,提示fMET-FPR1信号通路驱动中性粒细胞活化。
要点
- DM和IBM患者血浆fMET水平显著高于健康对照(DM P<0.0001;IBM P=0.0002)。
- 抗体阴性IBM中fMET与MMT8呈负相关(r=-0.53,P=0.02)。
- FPR1抑制显著降低DM和IBM血浆诱导的中性粒细胞活化。
核心结论
- 研究显示fMET-FPR1信号驱动DM和IBM中性粒细胞活化,促进炎症和肌肉损伤。
- 作者认为靶向该通路可能为特发性炎性肌病提供新的治疗方法。
研究设计与样本
- 研究纳入IBM患者46例、DM患者40例和健康对照40例,检测血浆fMET、钙卫蛋白、中性粒细胞弹性蛋白酶-DNA(NE-DNA)复合物和细胞因子。
- 采用流式细胞术评估血浆刺激(加或不加FPR1抑制)后中性粒细胞标志物CD11b和CD66b。
- 分析fMET与肌力(MMT8)及中性粒细胞活化标志物的相关性。
主要发现
- DM和IBM患者血浆fMET水平显著高于对照(DM P<0.0001;IBM P=0.0002)。
- fMET中位数:IBM为13719 pg/ml(第75百分位17236 pg/ml),DM为14780 pg/ml(第75百分位17631 pg/ml),对照为8449 pg/ml(第75百分位12632 pg/ml)。
- fMET与抗体阴性IBM的MMT8呈负相关(r=-0.53,P=0.02)。
- 钙卫蛋白在DM中升高(P=0.01),在IBM中未升高;NE-DNA复合物在DM(P=0.03)和IBM(P<0.0001)中均升高。
- FPR1抑制显著降低DM(P<0.0001)和IBM(P=0.0012)血浆诱导的中性粒细胞活化,使CD66b恢复至对照水平,部分恢复CD11b。
关键数值与推荐
- DM和IBM患者血浆fMET水平显著高于对照(DM P<0.0001;IBM P=0.0002)。
- fMET中位数:IBM 13719 pg/ml(第75百分位17236 pg/ml),DM 14780 pg/ml(第75百分位17631 pg/ml),对照8449 pg/ml(第75百分位12632 pg/ml)。
- 抗体阴性IBM中fMET与MMT8负相关(r=-0.53,P=0.02)。
- 钙卫蛋白在DM升高(P=0.01),IBM未升高;NE-DNA复合物在DM(P=0.03)和IBM(P<0.0001)升高。
- FPR1抑制降低DM(P<0.0001)和IBM(P=0.0012)血浆诱导的中性粒细胞活化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Neutrophil activation is heightened in inflammatory myopathies and associated with disease activity, yet its mechanisms remain unclear. This study explores the role of N-formyl methionine (fMET) in formyl peptide receptor 1 (FPR1)-mediated neutrophil activation in idiopathic inflammatory myopathies (IIMs), focusing on dermatomyositis (DM) and inclusion body myositis (IBM). METHODS: Plasma from IBM (n = 46), DM (n = 40) and healthy controls (n = 40) was analysed for fMET, calprotectin, neutrophil elastase DNA (NE-DNA) and cytokines using ELISA. Neutrophil markers CD11b and CD66b were assessed by flow cytometry following plasma stimulation with or without FPR1 inhibition. Correlation analyses were performed between fMET, muscle strength (MMT8) and neutrophil activation markers. RESULTS: DM and IBM patients had significantly higher plasma fMET levels than controls (P < 0.0001 for DM; P = 0.0002 for IBM). Median fMET levels were 13 719 pg/ml (75th percentile: 17 236 pg/ml) for IBM, 14 780 pg/ml (75th percentile: 17 631 pg/ml) for DM and 8449 pg/ml (75th percentile: 12 632 pg/ml) for controls. fMET correlated inversely with MMT8 in antibody-negative IBM (r = -0.53, P = 0.02). Calprotectin was elevated in DM (P = 0.01) but not IBM; NE-DNA complexes were increased in both DM (P = 0.03) and IBM (P < 0.0001). FPR1 inhibition significantly reduced plasma-induced neutrophil activation in DM (P < 0.0001) and IBM (P = 0.0012), restoring CD66b and partially CD11b to control levels. CONCLUSION: Our findings show that fMET-FPR1 signalling drives neutrophil activation in DM and IBM, promoting inflammation and muscle damage. Targeting this pathway may offer a novel IIM therapy.
引用
- Gonzalez-Chapa JA, Horuluoglu B, Notarnicola A, et al. N-formyl methionine peptide-driven neutrophil activation in idiopathic inflammatory myopathies. Rheumatology (Oxford). 2026. PMID: 40971811. doi:10.1093/rheumatology/keaf495
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。